六周低分子肝素对比十二周华法林治疗小腿深静脉血栓:一项随机、前瞻性、开放标签研究
多中心开放标签随机非劣效试验纳入260例症状性孤立性远端深静脉血栓门诊患者,比较6周中等剂量低分子肝素与12周华法林。因招募缓慢提前终止,结果显示华法林组主要疗效终点事件少于低分子肝素组,风险差0.069(95%CI 0.006-0.132),风险比2.8(95%CI 1.04-7.55)。
要点
- 6周低分子肝素组主要疗效终点事件14例(10.8%),12周华法林组5例(3.8%)。
- 低分子肝素组IDDVT复发率10.0%,华法林组3.1%(p=.024)。
- 临床相关出血低分子肝素组2例(1.6%),华法林组1例(0.8%)(p=.56)。
核心结论
- 在这组孤立性远端深静脉血栓门诊患者中,12周华法林似乎在降低静脉血栓栓塞复发风险方面优于6周低分子肝素。
研究设计与样本
- 多中心、开放标签、随机、前瞻性非劣效试验,纳入260例症状性孤立性远端深静脉血栓门诊患者。
- 患者随机接受低分子肝素后序贯维生素K拮抗剂共12周,或低分子肝素1 mg/kg皮下注射每日两次共2周后改为1 mg/kg皮下注射每日一次共4周。
- 随访6个月,主要终点为复发性静脉血栓栓塞的复合指标,包括孤立性远端深静脉血栓复发或延伸、近端深静脉血栓和肺栓塞。
- 研究因招募速度缓慢提前终止。
主要发现
- 主要疗效终点事件在低分子肝素组14例(10.8%),华法林组5例(3.8%);风险差0.069(95%CI 0.006-0.132),风险比2.8(95%CI 1.04-7.55)。
- 华法林组发生1例肺栓塞,低分子肝素组发生1例近端深静脉血栓。
- 孤立性远端深静脉血栓复发率低分子肝素组10.0%,华法林组3.1%(p=.024)。
- 临床相关出血低分子肝素组2例(1.6%),华法林组1例(0.8%)(p=.56)。
关键数值与推荐
- 当前指南建议孤立性远端深静脉血栓抗凝治疗3个月,但临床实践中常采用更短疗程。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因招募速度缓慢提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current guidelines suggest a 3-month anticoagulant treatment course for isolated distal deep vein thrombosis (IDDVT), but shorter durations of treatment are frequently prescribed in clinical practice. We investigated whether a 6-week treatment with low-molecular-weight heparin (LMWH) at intermediate dosage can be an effective and safe alternative to vitamin K antagonists (VKA) in patients with IDDVT (non-inferiority trial). In a multicenter, open-label, randomized trial, 260 outpatients with symptomatic IDDVT were randomly assigned to receive either LMWH followed by VKA for 12 weeks or LMWH 1 mg/kg subcutaneously twice a day for 2 weeks followed by 1 mg/kg subcutaneously once a day for 4 weeks. The follow-up was 6 months and the primary endpoint was the composite measure of recurrent venous thromboembolism (VTE) defined as: recurrence or extension of IDDVT, proximal DVT, and pulmonary embolism (PE). The study was stopped prematurely due to slow recruiting rates. The primary efficacy outcome occurred in 14 patients receiving LMWH (10.8%) and in five patients receiving VKA (3.8%); risk difference was 0.069 (95% CI: 0.006-0.132), hazard ratio 2.8 (95% CI: 1.04-7.55). There was one PE in the VKA group and one proximal DVT in the LMWH group. IDDVT recurrence was 10.0% in the LMWH group versus 3.1% in the VKA group (p = .024). Two patients had clinically relevant bleedings (1.6%) in the LMWH group versus one (0.8%) in VKA group (p = .56). In conclusion, VKA for 12 weeks seems superior to LMWH for 6 weeks in reducing the risk of VTE recurrences in our cohort of outpatients with IDDVT.
引用
- Sartori M, Iotti M, Camporese G, et al. Six-week low-molecular-weight heparin versus 12-week warfarin for calf deep vein thrombosis: A randomized, prospective, open-label study. Am J Hematol. 2024. PMID: 38375893. doi:10.1002/ajh.27255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。